

**Clinical trial results:****A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency****Summary**

EudraCT number	2014-000533-22
Trial protocol	GB IT FI
Global end of trial date	30 October 2018

Results information

Result version number	v2 (current)
This version publication date	18 December 2019
First version publication date	23 May 2019
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Updates made to align with presentation of study results on ClinicalTrials.gov.

Trial information**Trial identification**

Sponsor protocol code	LAL-CL08
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02193867
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Alexion Pharmaceuticals Inc.
Sponsor organisation address	121 Seaport Blvd., Boston, MA, United States, 02210
Public contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com
Scientific contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 October 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 October 2018
Global end of trial reached?	Yes
Global end of trial date	30 October 2018
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to evaluate the safety and tolerability of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency.

Protection of trial subjects:

This study was conducted in accordance with International Council on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the countries in which the study was conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 May 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 8
Country: Number of subjects enrolled	Finland: 1
Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	10
EEA total number of subjects	9

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	1
Infants and toddlers (28 days-23 months)	9
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

A total of 6 sites were initiated, and participants were treated at 5 sites in 3 countries (United Kingdom [UK], United States [US], Finland). One study site in the US was initiated but did not screen or treat any participants.

Pre-assignment

Screening details:

The study consisted of a screening period of up to 3 weeks. Participants who met all eligibility criteria were enrolled, treated, and analysed.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Open-Label Sebelipase Alfa
-----------	----------------------------

Arm description:

All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (UK only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.

Arm type	Experimental
Investigational medicinal product name	Sebelipase Alfa
Investigational medicinal product code	
Other name	SBC-102
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

All participants initiated treatment with sebelipase alfa at dose of 1 mg/kg qw. Dose escalations to 3 mg/kg qw, 5 mg/kg qw, or 7.5 mg/kg qw (UK only) were permitted for individual participants who met pre-defined dose escalation criteria. A change in dose frequency and dose reductions were permitted in the event of poor tolerability. Participants who did not tolerate a dose of 3 mg/kg qw could receive a dose reduction to 1 mg/kg qw. A participant who could not tolerate a dose of 1 mg/kg qw, despite measures taken to manage infusion-associated reactions, was to be discontinued from the study. All dose reductions were undertaken after consultation between the Investigator and Sponsor and, where appropriate, the safety committee.

Number of subjects in period 1	Open-Label Sebelipase Alfa
Started	10
Received At Least 1 Dose Of Study Drug	10
Completed 18 Months Of Treatment	8
Completed	6
Not completed	4
Sponsor Study Termination	2
Death	2

Baseline characteristics

Reporting groups

Reporting group title	Open-Label Sebelipase Alfa
-----------------------	----------------------------

Reporting group description:

All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (UK only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.

Reporting group values	Open-Label Sebelipase Alfa	Total	
Number of subjects	10	10	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	1	1	
Infants and toddlers (28 days-23 months)	9	9	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: months			
arithmetic mean	4.13		
standard deviation	± 2.859	-	
Gender categorical			
Units: Subjects			
Female	5	5	
Male	5	5	
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska native	1	1	
Asian	6	6	
White	1	1	
Egyptian	1	1	
Turkish Kurdish	1	1	

End points

End points reporting groups

Reporting group title	Open-Label Sebelipase Alfa
-----------------------	----------------------------

Reporting group description:

All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (UK only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.

Subject analysis set title	Full Analysis Set (FAS)
Subject analysis set type	Full analysis

Subject analysis set description:

All participants who received any amount of sebelipase alfa (1.0, 3.0, 5.0, or 7.5 mg/kg qw) during the study and where applicable, met end-point criteria.

Primary: Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)

End point title	Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs) ^[1]
-----------------	---

End point description:

The number of participants experiencing severe TEAEs is presented for participants who received sebelipase alfa in this open-label study. Adverse events were obtained through spontaneous reporting or elicited by specific questioning or examination of the participant's parent or legal guardian. An adverse event was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant, whether or not causally related to administration of study drug. Adverse event severity was graded by the Investigator as mild, moderate, or severe based on definitions developed from Clinical Data Interchange Standards Consortium Study Data Tabulation Model standard terminology v3.1.1. Adverse events reporting was from the date of informed consent until completion of the follow-up visit at approximately 30 days after the last dose of study drug. A summary of all serious and other nonserious AEs regardless of causality is located in the Adverse Events section.

End point type	Primary
----------------	---------

End point timeframe:

Screening through Month 37

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Quantitative statistical analyses were not conducted on any of the reported safety data.

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	10 ^[2]			
Units: Participants	7			

Notes:

[2] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage Of Participants Surviving To 12, 18, 24, And 36 Months Of Age

End point title	Percentage Of Participants Surviving To 12, 18, 24, And 36 Months Of Age
End point description: The percentage of participants in the FAS who survived to 12, 18, 24, and 36 months of age. The exact confidence interval was calculated using the Clopper-Pearson method. Participants with unknown survival status at the age specified in the analysis were excluded. At 36 months, there were 2 participants who were alive and still on study who had not yet reached the age specified in the analysis. As such, these participants were excluded from the calculation of percent surviving.	
End point type	Secondary
End point timeframe: Baseline through Month 12, Month 18, Month 24, and Month 36	

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: percentage of participants				
number (confidence interval 95%)				
12 Months	90 (55.5 to 99.7)			
18 Months	80 (44.4 to 97.5)			
24 Months	80 (44.4 to 97.5)			
36 Months	75 (34.9 to 96.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Median Age At Death

End point title	Median Age At Death
End point description: Age at death for participants who died during the study. All deaths were assessed by the Investigator as unrelated to study drug.	
End point type	Secondary
End point timeframe: Baseline through Month 36	

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	2 ^[3]			
Units: Months				
median (full range (min-max))	9.33 (4.9 to 13.8)			

Notes:

[3] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline In Percentiles For Weight For Age (WFA) At 12, 24, And 36 Months

End point title	Change From Baseline In Percentiles For Weight For Age (WFA) At 12, 24, And 36 Months
-----------------	--

End point description:

This end point evaluated the effects of sebelipase alfa on growth by measuring the changes from baseline in percentiles for WFA. Percentiles for WFA were summarized as observed values by visit. Baseline was defined as the last available assessment prior to the first infusion of sebelipase alfa.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 12, Month 24, and Month 36

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	9 ^[4]			
Units: Percentile				
median (full range (min-max))				
Month 12 (N=8)	27.760 (1.34 to 67.58)			
Month 24 (N=8)	41.276 (7.54 to 63.77)			
Month 36 (N=5)	59.310 (36.39 to 72.51)			

Notes:

[4] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Number Of Participants With Stunting, Wasting, Or Underweight At Baseline, 12, 24, And 36 Months

End point title	Number Of Participants With Stunting, Wasting, Or Underweight At Baseline, 12, 24, And 36 Months
-----------------	---

End point description:

The number of participants who met criteria for the following 3 dichotomous indicators of under nutrition were reported. These indicators included the following:

1. Stunting was defined as at least 2 standard deviations below the median for length-for-age/height-for-age.
2. Wasting was defined as wasting at least 2 standard deviations below the median for weight-for-length/weight-for-height.
3. Underweight was defined as at least 2 standard deviations below the median for WFA.

End point type	Secondary
End point timeframe:	
Baseline to Month 12, Month 24, and Month 36	

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	10 ^[5]			
Units: Participants				
Stunting, Baseline (N=9)	4			
Stunting, Month 12 (N=8)	0			
Stunting, Month 24 (N=8)	0			
Stunting, Month 36 (N=5)	0			
Wasting, Baseline (N=9)	5			
Wasting, Month 12 (N=8)	0			
Wasting, Month 24 (N=8)	0			
Wasting, Month 36 (N=5)	0			
Underweight, Baseline (N=10)	6			
Underweight, Month 12 (N=8)	0			
Underweight, Month 24 (N=8)	0			
Underweight, Month 36 (N=5)	0			

Notes:

[5] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline In Serum Transaminases (ALT And AST) At Month 12, 24, And 36

End point title	Change From Baseline In Serum Transaminases (ALT And AST) At Month 12, 24, And 36
-----------------	---

End point description:

This end point evaluated the effects of sebelipase alfa on liver function by measuring the change from baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at months 12, 24, and 36. Results are reported in units/liter (U/L).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 12, Month 24, and Month 36

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	10 ^[6]			
Units: U/L				
median (full range (min-max))				
ALT: Month 12 (N=7)	0 (-175 to 66)			
ALT: Month 24 (N=7)	14.0 (-207 to 80)			
ALT: Month 36 (N=4)	-42.0 (-224 to 6)			
AST: Month 12 (N=6)	-33.5 (-322 to 8)			
AST: Month 24 (N=5)	-4.0 (-90 to 36)			
AST: Month 36 (N=3)	-101.0 (-351 to -9)			

Notes:

[6] - FAS

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline In Serum Ferritin At Month 12, 24, And 36

End point title	Change From Baseline In Serum Ferritin At Month 12, 24, And 36
-----------------	--

End point description:

The median change in the inflammatory marker serum ferritin from Baseline to Months 12, 24, and 36 is presented. The number of participants analyzed reflects only those from the FAS who had both a baseline value and a value at the indicated timepoint (Months 12, 24, and 36). Results are reported in micrograms (ug)/L.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 12, Month 24, and Month 36

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	2 ^[7]			
Units: ug/L				
median (full range (min-max))				
Month 12 (N=1)	-2957.00 (-2957.0 to -2957.0)			
Month 24 (N=2)	-1722.00 (-2984.0 to -460.0)			
Month 36 (N=0)	0 (0 to 0)			

Notes:

[7] - Participants in the FAS who had both a baseline value and a value at the indicated timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization (TFHN)

End point title	Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization (TFHN)
-----------------	---

End point description:

The number of participants achieving and maintaining TFHN are presented. For TFHN to be achieved, the participant had to meet the following criteria:

1. Two post baseline measurements of hemoglobin, at least 4 weeks apart, were above the age-adjusted lower limit of normal (LLN);
2. No known additional measurements of hemoglobin were below the age-adjusted LLN during the (minimum) 4 week period;
3. No transfusions were administered to the participant during the (minimum) 4 week period, or for 2 weeks prior to the first hemoglobin measurement in the (minimum) 4 week period.

If all 3 criteria were met, a participant was considered to have achieved TFHN on the date of the first hemoglobin assessment in the 4 week period.

A participant was considered to have maintained TFHN if he/she was transfusion free at Week 6 and had no abnormally low hemoglobin levels (levels below the age adjusted LLN) beginning at Week 8 of the study and continuing for at least 13 weeks (3 months).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through Month 36

End point values	Open-Label Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	10 ^[8]			
Units: Participants				
Achieved TFHN	7			
Maintained TFHN	0			

Notes:

[8] - FAS

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Screening (up to 21 days prior to start of treatment) to Month 37 (approximately 30 days after the last dose of study drug).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Sebelipase Alfa: 1.0 mg/kg qw
-----------------------	-------------------------------

Reporting group description:

This reporting group is based on the FAS and includes AEs with onset during the administration of IV treatment of sebelipase alfa at a dose of 1.0 mg/kg qw. All 10 participants in the FAS received sebelipase alfa at a dose of 1.0 mg/kg qw.

Reporting group title	Sebelipase Alfa: 3.0 mg/kg qw
-----------------------	-------------------------------

Reporting group description:

This reporting group is based on the FAS and includes AEs with onset during the administration of IV treatment of sebelipase alfa at a dose of 3.0 mg/kg qw. Nine of the 10 participants in the FAS received sebelipase alfa at a dose of 3.0 mg/kg qw.

Reporting group title	Sebelipase Alfa: 5.0 mg/kg qw
-----------------------	-------------------------------

Reporting group description:

This reporting group is based on the FAS and includes AEs with onset during the administration of IV treatment of sebelipase alfa at a dose of 5.0 mg/kg qw. Seven of the 10 participants in the FAS received sebelipase alfa at a dose of 5.0 mg/kg qw.

Reporting group title	Sebelipase Alfa: 7.5 mg/kg qw
-----------------------	-------------------------------

Reporting group description:

This reporting group is based on the FAS and includes AEs with onset during the administration of IV treatment of sebelipase alfa at a dose of 7.5 mg/kg qw (UK only). One of the 10 participants in the FAS received sebelipase alfa at a dose of 7.5 mg/kg qw.

Serious adverse events	Sebelipase Alfa: 1.0 mg/kg qw	Sebelipase Alfa: 3.0 mg/kg qw	Sebelipase Alfa: 5.0 mg/kg qw
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 10 (80.00%)	8 / 9 (88.89%)	7 / 7 (100.00%)
number of deaths (all causes)	1	0	1
number of deaths resulting from adverse events			
Vascular disorders			
Bloody discharge			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flushing			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poor venous access			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava occlusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venoocclusive disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Bone marrow transplant			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Catheter site haemorrhage			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hypothermia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	6 / 9 (66.67%)	3 / 7 (42.86%)
occurrences causally related to treatment / all	0 / 1	0 / 12	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Adenoidal hypertrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Sleep apnoea syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachypnoea			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritability			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embedded device			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Body temperature fluctuation			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Body temperature increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug specific antibody absent			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sapovirus test positive			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Skull fracture			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transfusion reaction			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Pericardial effusion	Additional description: The single occurrence of pericardial effusion in the 1.0 mg/kg qw group lead to death and was assessed by the Investigator as unrelated to study drug.		
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sinus bradycardia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	1 / 2	5 / 5	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Abdominal lymphadenopathy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histiocytosis haematophagic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	4 / 9 (44.44%)	2 / 7 (28.57%)
occurrences causally related to treatment / all	0 / 0	1 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip swelling			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malabsorption			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue erythema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	1 / 10 (10.00%)	5 / 9 (55.56%)	4 / 7 (57.14%)
occurrences causally related to treatment / all	0 / 2	1 / 8	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Liver disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrotic syndrome			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oliguria			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess bacterial			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup infectious			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	3 / 7 (42.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis viral			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 10 (20.00%)	6 / 9 (66.67%)	3 / 7 (42.86%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis adenovirus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lice infestation			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal infection			
subjects affected / exposed ^[1]	0 / 5 (0.00%)	0 / 5 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis	Additional description: The single occurrence of sepsis in the 5.0 mg/kg qw group lead to death and was assessed by the Investigator as unrelated to study drug.		
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Staphylococcal skin infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site infection			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis streptococcal			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	3 / 9 (33.33%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Feeding disorder			
subjects affected / exposed	1 / 10 (10.00%)	3 / 9 (33.33%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Sebelipase Alfa: 7.5 mg/kg qw		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Vascular disorders			
Bloody discharge			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flushing			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Poor venous access			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Superior vena cava occlusion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venoocclusive disease			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Bone marrow transplant			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Catheter site haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Complication associated with device			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypothermia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		

Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Adenoidal hypertrophy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sleep apnoea syndrome			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachypnoea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Tonsillar hypertrophy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Irritability			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device occlusion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embedded device			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Body temperature fluctuation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Body temperature increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Drug specific antibody absent			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sapovirus test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Weight decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Skull fracture			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transfusion reaction			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Pericardial effusion	Additional description: The single occurrence of pericardial effusion in the 1.0 mg/kg qw group lead to death and was assessed by the Investigator as unrelated to study drug.		
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus bradycardia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Tachycardia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Abdominal lymphadenopathy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Histiocytosis haematophagic			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iron deficiency anaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Gastritis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lip swelling			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malabsorption			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tongue erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Liver disorder			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hyperhidrosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urticaria			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrotic syndrome			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oliguria			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess bacterial			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Catheter site infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Croup infectious				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related sepsis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ear infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia sepsis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis viral				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis adenovirus				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis norovirus				

subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis rotavirus				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis viral				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lice infestation				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Otitis media				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Parainfluenzae virus infection				
subjects affected / exposed	0 / 1 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus bronchiolitis				

subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection viral			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rhinovirus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scrotal infection			
subjects affected / exposed ^[1]	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis	Additional description: The single occurrence of sepsis in the 5.0 mg/kg qw group lead to death and was assessed by the Investigator as unrelated to study drug.		
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal skin infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stoma site infection			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis streptococcal			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Feeding disorder			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malnutrition			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Only male participants were exposed to this adverse event.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Sebelipase Alfa: 1.0 mg/kg qw	Sebelipase Alfa: 3.0 mg/kg qw	Sebelipase Alfa: 5.0 mg/kg qw
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 10 (90.00%)	9 / 9 (100.00%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Vascular disorders			
Hyperaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Hypotension			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Lymphodema			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Microangiopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Poor venous access			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Superior vena cava occlusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Catheter site bruise			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Catheter site discharge			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Catheter site erythema			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	1	2	2
Catheter site extravasation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	2
Catheter site granuloma			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Catheter site swelling			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Complication associated with device			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Crying			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Face oedema			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Feeling cold			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypertrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypothermia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Inflammation			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Mass			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	3 / 7 (42.86%)
occurrences (all)	3	1	3
Oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Pain			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	0	2	2
Pyrexia			
subjects affected / exposed	7 / 10 (70.00%)	7 / 9 (77.78%)	5 / 7 (71.43%)
occurrences (all)	15	43	36
Swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Vaccination site pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Vessel puncture site discharge			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Allergy to animal			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Anaphylactic reaction subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 2
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	0 / 7 (0.00%) 0
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed ^[2] occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 3 (33.33%) 1
Respiratory, thoracic and mediastinal disorders Adenoidal hypertrophy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Asthma subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 6	4 / 9 (44.44%) 19	4 / 7 (57.14%) 8
Epistaxis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	3 / 7 (42.86%) 6
Nasal congestion subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	3 / 9 (33.33%) 5	0 / 7 (0.00%) 0
Nasal oedema subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	0 / 7 (0.00%) 0
Pharyngeal erythema			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Pulmonary oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Respiratory acidosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Respiratory distress			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	3 / 7 (42.86%)
occurrences (all)	2	1	8
Rhinorrhoea			
subjects affected / exposed	1 / 10 (10.00%)	3 / 9 (33.33%)	4 / 7 (57.14%)
occurrences (all)	1	6	6
Sneezing			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Tachypnoea			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	4	0
Tonsillar erythema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Use of accessory respiratory muscles			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Wheezing			

subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	2 / 9 (22.22%) 2	2 / 7 (28.57%) 2
Psychiatric disorders			
Agitation			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	2	3	1
Drug abuse			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Irritability			
subjects affected / exposed	3 / 10 (30.00%)	4 / 9 (44.44%)	0 / 7 (0.00%)
occurrences (all)	3	5	0
Restlessness			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Staring			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Stress			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Product issues			
Device breakage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Device dislocation			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Device infusion issue			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Device occlusion			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	4 / 7 (57.14%)
occurrences (all)	0	4	4
Investigations			

Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 2	1 / 7 (14.29%) 1
Alpha 1 foetoprotein increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Alpha-1 anti-trypsin increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Antibody test positive subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Bacterial test positive subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Beta-2 glycoprotein antibody subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Blood albumin decreased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Blood aldosterone decreased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Blood aldosterone increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Blood alkaline phosphatase decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Blood calcium decreased			

subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	2	3	0
Blood cholesterol increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Blood fibrinogen decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood fibrinogen increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Blood glucose fluctuation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood glucose increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Blood iron decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Blood parathyroid hormone			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood potassium decreased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Blood pressure abnormal			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	4	0	0
Blood pressure increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences (all)	2	2	2

Blood sodium decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Blood triglycerides decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	1 / 7 (14.29%) 1
Blood urea decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Blood urea increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Blood uric acid decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Body temperature subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Body temperature abnormal subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	1 / 7 (14.29%) 1
Body temperature decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Body temperature increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 9 (11.11%) 2	1 / 7 (14.29%) 4
Brucella test positive subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	1 / 9 (11.11%) 3	1 / 7 (14.29%) 5

Cardiac murmur			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Cortisol increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Drug specific antibody			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Drug specific antibody present			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Faecal calprotectin increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Fibrin D dimer increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Gastric fluid analysis abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Heart rate increased			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
High density lipoprotein decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Human rhinovirus test positive			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Liver function test abnormal			

subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Low density lipoprotein increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Nasogastric output abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Neutrophil count increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Nitrite urine present			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Norovirus test positive			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Osmolar gap increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Parvovirus B19 test positive			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Procalcitonin increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Protein total decreased			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	2	0	2
Prothrombin level decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Prothrombin time prolonged			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Renal function test abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Renin decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Renin increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Respiratory rate increased			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Serum ferritin increased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	1	2	1
Staphylococcus test positive			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vitamin A decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vitamin D decreased			
subjects affected / exposed	3 / 10 (30.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	3	1	1
Vitamin E decreased			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	3	1	1
Weight decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural			

complications			
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	2	2
Drug administration error			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Gastrostomy tube site complication			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Head injury			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	2	1	0
Laceration			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Ligament sprain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Overdose			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Scar			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Stoma site erythema			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	1 / 7 (14.29%) 1
Stoma site extravasation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Stoma site haemorrhage subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 2	0 / 7 (0.00%) 0
Stoma site hypergranulation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 3	1 / 7 (14.29%) 1
Congenital, familial and genetic disorders			
Atrial septal defect subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Chimerism subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Chromosomal deletion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Hydrocele subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	2 / 9 (22.22%) 2	2 / 7 (28.57%) 3
Cardiac septal hypertrophy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Cardiomyopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Cyanosis			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Left ventricular dilatation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	5 / 10 (50.00%)	6 / 9 (66.67%)	3 / 7 (42.86%)
occurrences (all)	8	13	5
Nervous system disorders			
Petit mal epilepsy			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Somnolence			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	2	2	4
Febrile neutropenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	3
Hypochromasia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Iron deficiency anaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Leukocytosis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	2	2
Leukopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Lymph node calcification			

subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Lymphadenopathy			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences (all)	1	1	2
Lymphocytosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Microcytosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Neutrophilia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Thrombocytopenia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Thrombocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	3
Eye disorders			
Eye discharge			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences (all)	0	1	2
Eyelid oedema			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
Eyelid rash			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Ocular hyperaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Abdominal distension			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	3	0	2
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	1 / 7 (14.29%)
occurrences (all)	0	6	1
Aphthous ulcer			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Chapped lips			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	2	5	4
Diarrhoea			
subjects affected / exposed	4 / 10 (40.00%)	5 / 9 (55.56%)	5 / 7 (71.43%)
occurrences (all)	12	23	29
Faeces hard			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	2
Gastrooesophageal reflux disease			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Haematemesis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Infantile spitting up			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Inguinal hernia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Lip dry			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lip swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Teething			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	2 / 7 (28.57%)
occurrences (all)	0	5	2
Vomiting			
subjects affected / exposed	5 / 10 (50.00%)	6 / 9 (66.67%)	4 / 7 (57.14%)
occurrences (all)	11	15	11
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hepatic calcification			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Dermatitis diaper			
subjects affected / exposed	3 / 10 (30.00%)	3 / 9 (33.33%)	3 / 7 (42.86%)
occurrences (all)	5	9	4
Dry skin			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	4
Eczema			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences (all)	2	1	2
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	5	1	0
Pigmentation disorder			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	1	2	1
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	1	2	2
Pruritus generalised			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Rash			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	2	4	4
Rash generalised			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Rash erythematous			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Rash papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Rash pruritic			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Red man syndrome			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Scar pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Skin disorder			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Skin exfoliation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Skin irritation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Swelling face			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	2	3
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0

Renal impairment subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Urinary retention subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders Joint swelling subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Infections and infestations Abscess limb subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Adenoviral upper respiratory infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Bacteraemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Candida infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	0 / 7 (0.00%) 0
Candida nappy rash subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	0 / 7 (0.00%) 0
Catheter site abscess subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Cytomegalovirus viraemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 9 (0.00%) 0	1 / 7 (14.29%) 1
Device related infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	4 / 9 (44.44%) 5	2 / 7 (28.57%) 5
Device related sepsis			

subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	2	2	3
Enterococcal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Escherichia urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Exanthema subitum			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Eye infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Eye infection bacterial			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Fungal infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Gastroenteritis norovirus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Gastroenteritis sapovirus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Influenza			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Nasopharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	2 / 7 (28.57%)
occurrences (all)	4	2	4
Oral candidiasis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Otitis media			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	2	2
Parainfluenzae virus infection			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Parechovirus infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Rhinitis			
subjects affected / exposed	2 / 10 (20.00%)	4 / 9 (44.44%)	2 / 7 (28.57%)
occurrences (all)	2	8	7

Rhinovirus infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	2 / 7 (28.57%)
occurrences (all)	0	1	4
Sepsis			
subjects affected / exposed	2 / 10 (20.00%)	4 / 9 (44.44%)	1 / 7 (14.29%)
occurrences (all)	2	4	7
Skin infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Staphylococcal infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Stoma site infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	3 / 7 (42.86%)
occurrences (all)	1	2	3
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
Adenovirus infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	2
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	4	0	1
Electrolyte imbalance			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Feeding disorder			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Fluid overload			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypernatraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Hypocalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	1 / 7 (14.29%)
occurrences (all)	0	4	1
Hypoglycaemia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	4
Hypokalaemia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
Hyponatraemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	2	0	2
Hypophagia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Hyposideraemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Hypovitaminosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	2
Hypovolaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 9 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Iron deficiency			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Malnutrition			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	0 / 7 (0.00%)
occurrences (all)	3	1	0
Metabolic acidosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vitamin A deficiency			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Vitamin D deficiency			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	2
Vitamin E deficiency			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Sebelipase Alfa: 7.5 mg/kg qw		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Skin papilloma subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Vascular disorders			
Hyperaemia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Hypertension subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Hypotension subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Lymphodema subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Microangiopathy subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Poor venous access subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Superior vena cava occlusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
General disorders and administration site conditions			
Catheter site bruise subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Catheter site discharge subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Catheter site erythema subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Catheter site extravasation			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Catheter site granuloma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Catheter site swelling			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Complication associated with device			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Crying			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Feeling cold			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypertrophy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypothermia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Inflammation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Injection site erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Mass			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Oedema			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	5		
Swelling			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vaccination site pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vessel puncture site discharge			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Allergy to animal			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Anaphylactic reaction			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Drug hypersensitivity			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypersensitivity			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed ^[2]	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Adenoidal hypertrophy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Asthma			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nasal oedema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pharyngeal erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pulmonary oedema			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory acidosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory distress			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Sneezing			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Tachypnoea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Tonsillar erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Tonsillar hypertrophy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Use of accessory respiratory muscles			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Drug abuse			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

Irritability subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Restlessness subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Staring subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Stress subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Product issues Device breakage subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Device dislocation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Device infusion issue subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Device occlusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Alpha 1 foetoprotein increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Alpha-1 anti-trypsin increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Antibody test positive			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Bacterial test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Beta-2 glycoprotein antibody			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood albumin decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood aldosterone decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood aldosterone increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood calcium decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood cholesterol increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood fibrinogen decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood fibrinogen increased			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood glucose fluctuation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood glucose increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood iron decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood parathyroid hormone			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood potassium decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood pressure abnormal			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood pressure increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood sodium decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood triglycerides decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood triglycerides increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

Blood urea decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood urea increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood uric acid decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Body temperature			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Body temperature abnormal			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Body temperature decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Body temperature increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Brucella test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
C-reactive protein increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Cardiac murmur			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Cortisol increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Drug specific antibody			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

Drug specific antibody present subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Faecal calprotectin increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Fibrin D dimer increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Gastric fluid analysis abnormal subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Heart rate increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
High density lipoprotein decreased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Human rhinovirus test positive subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Liver function test abnormal subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Low density lipoprotein increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Nasogastric output abnormal subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Neutrophil count increased			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nitrite urine present			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Norovirus test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Osmolar gap increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Oxygen saturation decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Parvovirus B19 test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Procalcitonin increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Protein total decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Prothrombin level decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Prothrombin time prolonged			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Renal function test abnormal			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Renin decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Renin increased			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory rate increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Serum ferritin increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Staphylococcus test positive			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Transaminases increased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin A decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin D decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin E decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Drug administration error			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Fall			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastrostomy tube site complication			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Head injury			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Laceration			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Overdose			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Scar			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Skin abrasion			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Stoma site erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Stoma site extravasation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Stoma site haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Stoma site hypergranulation			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Congenital, familial and genetic disorders			
Atrial septal defect subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Chimerism subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Chromosomal deletion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Hydrocele subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Cardiac septal hypertrophy subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Cardiomyopathy subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Cyanosis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Left ventricular dilatation subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Tachycardia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 3		
Nervous system disorders			

Petit mal epilepsy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Febrile neutropenia			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Hypochromasia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Iron deficiency anaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Leukocytosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lymph node calcification			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lymphadenopathy			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lymphocytosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Neutropenia			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Microcytosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Neutrophilia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Thrombocytosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eye disorders			
Eye discharge			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eyelid oedema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eyelid rash			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Ocular hyperaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abdominal distension			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Abdominal pain			

subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Aphthous ulcer			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Chapped lips			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Faeces hard			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastritis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Haematemesis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Infantile spitting up			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Inguinal hernia			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Intestinal obstruction			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lip dry			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lip swelling			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Teething			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hepatic calcification			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Dermatitis diaper			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eczema			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pigmentation disorder			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	5		
Pruritus generalised			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash generalised			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash papular			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Red man syndrome			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Scar pain			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Skin disorder			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		
Skin exfoliation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Skin irritation			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Swelling face			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Proteinuria			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Renal impairment			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Urinary retention			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			

Joint swelling subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Infections and infestations			
Abscess limb subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Adenoviral upper respiratory infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Bacteraemia subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Candida infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Candida nappy rash subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Catheter site abscess subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Cytomegalovirus viraemia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Device related infection subjects affected / exposed occurrences (all)	1 / 1 (100.00%) 1		
Device related sepsis subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Enterococcal infection subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0		
Escherichia urinary tract infection			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Exanthema subitum			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eye infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Eye infection bacterial			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Fungal infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastroenteritis norovirus			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Gastroenteritis sapovirus			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Otitis media			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Parainfluenzae virus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Parechovirus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Respiratory tract infection viral			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Rhinovirus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Sepsis			
subjects affected / exposed	1 / 1 (100.00%)		
occurrences (all)	1		

Skin infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Staphylococcal infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Stoma site infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Tonsillitis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Viral infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Adenovirus infection			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Electrolyte imbalance			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Feeding disorder			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Fluid overload			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypernatraemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypoglycaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hyponatraemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypophagia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hyposideraemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypovitaminosis			

subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Hypovolaemia			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Iron deficiency			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Malnutrition			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Metabolic acidosis			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin A deficiency			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		
Vitamin E deficiency			
subjects affected / exposed	0 / 1 (0.00%)		
occurrences (all)	0		

Notes:

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Only female participants were exposed to this adverse event.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 December 2014	Removed the requirement that a participant receive at least 4 infusions at a dose of 1 mg/kg qw before being considered for dose escalation to 3 mg/kg qw, provided that the participant still met other pre-defined dose escalation criteria based on clinical response.
07 January 2016	Modified to allow for dose escalation to 7.5 mg/kg qw at UK sites only. Dose escalation to 7.5 mg/kg qw was to be implemented only after a thorough case review, and following mutual agreement by the Investigator and Sponsor and approval by the safety committee.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/23348766>

<http://www.ncbi.nlm.nih.gov/pubmed/26312827>

<http://www.ncbi.nlm.nih.gov/pubmed/28179030>